Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Active not recruiting 2Enrolling by invitation 1

Sponsor Class

NIH 3

Study Type

Interventional 2Observational 1

Sponsor

Cancer Type

Classical hematology 4Other hematologic neoplasm 3Myeloid 2Lymphoid 1

Conditions

Leukemia, Myeloid, Acute 121Precursor Cell Lymphoblastic Leukemia-Lymphoma 79Leukemia, Lymphocytic, Chronic, B-Cell 65Hematologic Neoplasms 62Leukemia 52Myelodysplastic Syndromes 47Lymphoma 34Lymphoma, Non-Hodgkin 28Leukemia, Myelogenous, Chronic, BCR-ABL Positive 28Multiple Myeloma 20Burkitt Lymphoma 20Leukemia, Myelomonocytic, Chronic 19Recurrence 18Neoplasms 17Lymphoma, Large B-Cell, Diffuse 15Leukemia, B-Cell 14Hodgkin Disease 14Myeloproliferative Disorders 13Lymphoma, Mantle-Cell 12Lymphoma, Follicular 11Leukemia, Biphenotypic, Acute 11Waldenstrom Macroglobulinemia 10Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 10Lymphoma, B-Cell, Marginal Zone 10Lymphoma, B-Cell 10Anemia, Refractory, with Excess of Blasts 10Blast Crisis 8Primary Myelofibrosis 7Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 6Myelodysplastic-Myeloproliferative Diseases 6

Interventions

ibrutinib 1fludarabine phosphate 1Rituximab 1Pharmacogenomic Testing 1Lenalidomide 1Epoetin Alfa 1Cyclophosphamide 1CT-P10 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Anemia × Other hematologic neoplasm × 30 days × Clear all
NCT00001620 2026-05-29

Screening for Hematology Branch Protocols

National Institutes of Health Clinical Center (CC)

Enrolling by invitation
10,000 enrolled
Classical hematologyOther hematologic neoplasm

Cytopenia, Anemia, Disease, Hematologic Diseases, Neutropenia, Thrombocytopenia, Hematologic Neoplasms

NCT00843882 2026-05-29

Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia

National Cancer Institute (NCI)

Phase 3 Active not recruiting
247 enrolled 19 charts
Classical hematologyMyeloidOther hematologic neoplasm

Anemia, Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic

NCT02048813 2026-05-29

Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

National Cancer Institute (NCI)

Phase 3 Active not recruiting
529 enrolled 12 charts 1 FDA
Classical hematologyLymphoidOther hematologic neoplasm

Anemia, Leukemia, Lymphocytic, Chronic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡